Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.31
OPK's Cash-to-Debt is ranked lower than
58% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. OPK: 1.31 )
Ranked among companies with meaningful Cash-to-Debt only.
OPK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 18 Max: No Debt
Current: 1.31
Equity-to-Asset 0.76
OPK's Equity-to-Asset is ranked higher than
71% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. OPK: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
OPK' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.69 Max: 0.96
Current: 0.76
-0.41
0.96
Piotroski F-Score: 3
Altman Z-Score: 3.38
Beneish M-Score: -2.36
WACC vs ROIC
14.91%
-2.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -7.13
OPK's Operating Margin % is ranked lower than
77% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. OPK: -7.13 )
Ranked among companies with meaningful Operating Margin % only.
OPK' s Operating Margin % Range Over the Past 10 Years
Min: -31624.44  Med: -82.69 Max: -6
Current: -7.13
-31624.44
-6
Net Margin % -3.59
OPK's Net Margin % is ranked lower than
74% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. OPK: -3.59 )
Ranked among companies with meaningful Net Margin % only.
OPK' s Net Margin % Range Over the Past 10 Years
Min: -31688.9  Med: -92.47 Max: -2.05
Current: -3.59
-31688.9
-2.05
ROE % -2.14
OPK's ROE % is ranked lower than
71% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. OPK: -2.14 )
Ranked among companies with meaningful ROE % only.
OPK' s ROE % Range Over the Past 10 Years
Min: -3196.93  Med: -20.87 Max: -1.23
Current: -2.14
-3196.93
-1.23
ROA % -1.59
OPK's ROA % is ranked lower than
69% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. OPK: -1.59 )
Ranked among companies with meaningful ROA % only.
OPK' s ROA % Range Over the Past 10 Years
Min: -1352.71  Med: -13.26 Max: -0.83
Current: -1.59
-1352.71
-0.83
ROC (Joel Greenblatt) % -36.79
OPK's ROC (Joel Greenblatt) % is ranked lower than
78% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. OPK: -36.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -130662.93  Med: -258.52 Max: -38.15
Current: -36.79
-130662.93
-38.15
3-Year Revenue Growth Rate 101.30
OPK's 3-Year Revenue Growth Rate is ranked higher than
98% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. OPK: 101.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OPK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26 Max: 152
Current: 101.3
0
152
3-Year EPS without NRI Growth Rate -46.30
OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
95% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. OPK: -46.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.4  Med: -9.3 Max: 152.4
Current: -46.3
-69.4
152.4
GuruFocus has detected 2 Warning Signs with OPKO Health Inc $OPK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPK's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

OPK Guru Trades in Q2 2016

Paul Tudor Jones 27,173 sh (New)
Joel Greenblatt 267,485 sh (+786.33%)
Ken Fisher 37,826 sh (-0.11%)
Murray Stahl 66,333 sh (-1.30%)
Mario Gabelli 97,050 sh (-3.70%)
» More
Q3 2016

OPK Guru Trades in Q3 2016

Jim Simons 1,412,757 sh (New)
John Burbank 12,234 sh (New)
George Soros 59,837 sh (New)
Joel Greenblatt 535,214 sh (+100.09%)
Paul Tudor Jones 36,248 sh (+33.40%)
Ken Fisher 38,229 sh (+1.07%)
Mario Gabelli 97,050 sh (unchged)
Murray Stahl 60,179 sh (-9.28%)
» More
Q4 2016

OPK Guru Trades in Q4 2016

Ken Fisher 39,229 sh (+2.62%)
John Burbank Sold Out
George Soros Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Mario Gabelli 94,550 sh (-2.58%)
Murray Stahl 58,149 sh (-3.37%)
Joel Greenblatt 167,109 sh (-68.78%)
» More
Q1 2017

OPK Guru Trades in Q1 2017

Paul Tudor Jones 93,342 sh (New)
Murray Stahl 58,941 sh (+1.36%)
Mario Gabelli 94,550 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 38,979 sh (-0.64%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:MNK, NAS:AKRX, NYSE:CTLT, NAS:MDCO, OTCPK:STDAF, NYSE:TARO, NYSE:VRX, NAS:ENDP, NAS:IRWD, NYSE:PTHN, OTCPK:SWPIF, OTCPK:HYPMY, OTCPK:HKMPY, NAS:PCRX, OTCPK:EVTCY, NAS:HZNP, NAS:SUPN, NAS:RDUS, NAS:PAHC, NAS:EGRX » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Headquarter Location:USA
OPKO Health Inc is a diversified healthcare company. The Company's operating business segments are diagnostics and pharmaceutical.

Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

Top Ranked Articles about OPKO Health Inc

Weekly CEO Buys Highlights Insiders invest in OPKO, Plains GP, Twilio, Tallgrass Energy, Kite Pharma
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. Read more...
OPKO Announces Multiple Presentations at the 112th American Urological Association Annual Meeting 
CORRECTION -- OPKO Health Inc.
OPKO Health Reports 2016 Financial and Operating Results
OPKO Health to Announce 2017 First Quarter Financial Results on May 9, 2017
Weekly CEO Buys Highlights Insiders invest in Wells Fargo, OPKO, Texas Capital, PacWest and Guess?
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Insiders Roundup: NuStar Energy, Opko Health, Alphabet Largest insider buys and sales of the week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “April 2017” and All Insider Sales to “$5,000,000+.” Read more...
Weekly CEO Buys Highlights Insiders purchase shares of G-III Apparel, OPKO and Washington Prime
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors

IRVINE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Steven D. Rubin, J.D. has joined the Company’s board of directors. Mr. Rubin, age 56, has served as OPKO Health, Inc.’s (NASDAQ:OPK) Executive Vice President – Administration since May 2007 and as a director of since February 2007. Mr. Rubin is a member of The Frost Group, LLC, a private investment firm. He has extensive experience as a practicing lawyer, and as general counsel and board member to multiple public companies. Mr. Rubin currently serves on the board of directors for the following companies: VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing a next generation of vaccines; Cognit, Inc., a data and analytics company providing cloud-based mission-critical information and performance marketing solutions; Kidville, Inc., an operator of large, upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds; Non-Invasive Monitoring Systems, Inc., a medical device company; BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases; Cocrystal Pharma, Inc., a biotechnology company developing new treatments for viral diseases; Sevion Therapeutics, Inc., a clinical stage company which discovers and develops next-generation biologics for the treatment of cancer and immunological diseases; Castle Brands, Inc., a developer and marketer of premium brand spirits; and, Neovasc, Inc., a company developing and marketing medical specialty vascular devices. Mr. Rubin previously served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006. Mr. Rubin previously served as a director of the following companies: Dreams, Inc. ( MKT:DRJ), a vertically integrated sports licensing and products company; Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc.; and, PROLOR Biotech, Inc., prior to its acquisition by the Company in August 2013. About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com. Forward-Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the composition and experience of ChromaDex’s board of directors. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
[email protected]

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
[email protected]

Read more...
OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder

MIAMI, March 22, 2017 (GLOBE NEWSWIRE) -- OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc. (NASDAQ:OPK) announces that the Company has received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for OPKO’s oligonucleotide-based AntagoNAT (CUR-1916) for the treatment of Dravet Syndrome.  Currently, there is no approved treatment for Dravet Syndrome in the U.S.  On March 7, 2017, OPKO Health received orphan drug designation for CUR-1916 for the treatment of Dravet Syndrome from the European Commission.
Orphan drug designation provides certain marketing exclusivity, tax credits for research and a waiver of the New Drug Application user fee.  AntagoNAT, anti-Natural Antisense Transcripts, is an OPKO platform technology in which single strand oligonucleotide molecules are designed to interfere with regulatory gene expression in order to enhance production of endogenous functional proteins.  The AntagoNAT technology, part of CURNA Pharmaceuticals, acquired by OPKO in 2011, was further developed in OPKO’s Miami research laboratories under the direction of Jane Hsiao, Ph.D., OPKO’s Vice Chairman and Chief Technical Officer. OPKO has studied over 250 genes and confirmed involvement of natural antisense transcripts (NAT) in their regulatory pathways. Of those, 89 genes were demonstrated to be subject to significant upregulation of mRNA in in vitro screening, and seven AntagoNAT oligonucleotides have been validated in vivo to date. OPKO plans to initiate a clinical trial of CUR-1916 for treatment of Dravet Syndrome this year. Oligonucleotides are synthetic chemical compounds consisting of mixtures of modified DNAs and RNAs. Only five oligonucleotide compounds are approved by FDA for various indications and others have been reported to be in late phase clinical development. The majority of the compounds work by down regulating, or depressing transcription (anti-sense) or by correcting gene defects. CUR-1916 works by upregulating a defective gene to increase the production of functional protein. About FDA Orphan Drug Designation Under the Orphan Drug Act (ODA) the FDA grants Orphan Drug status to drugs, vaccines, and diagnostic agents intended to treat a disease affecting less than 200,000 American citizens. Under the ODA, orphan drug sponsors qualify for seven-year FDA administered market Orphan Drug Exclusivity, tax credits of up to 50% of R&D costs, R&D grants, waived FDA fees, protocol assistance and may get clinical trial tax incentives. What is Dravet Syndrome? Dravet Syndrome, also called severe myoclonic epilepsy of infancy (SMEI), is a severe form of epilepsy that affects children and adults. It is caused by defects in the SCN1A genes (voltage gated sodium channel) required for the proper function of brain cells. In Dravet Syndrome, seizures begin in the first year of life, and are most often associated with elevated body temperature (febrile convulsions). Later, other types of seizures occur, including status epilepticus (seizures lasting at least 5 minutes and requiring emergency medical care). From age 2, the child’s development begins to decline or reverse, and results in impaired mental and motor skills, leading to long term disability. Dravet Syndrome also qualifies as a Rare Pediatric Disease under Section 529 of Food, Drug, and Cosmetic Act (the FD&C Act). Dravet Syndrome is debilitating and the death rate is reported to be 10-15%. About OPKO Health OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation’s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in  phase 2 clinical trials, among  the new class of GLP-1 glucagon receptor dual agonists, and TT701, a selective  androgen receptor modulator  for benign prostatic hyperplasia  (phase 2). Our biologics business includes hGH-CTP, a once weekly human growth hormone in phase 3 and partnered with Pfizer; and a long-acting Factor VIIa drug for hemophilia in phase 2a.   More information available at www.opko.com Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expectations about CUR-1916 and its effectiveness in treating Dravet syndrome, whether the drug will receive orphan designation in the U.S., whether we will commence clinical trials for CUR-1916 this year or at all,  whether the data from any of our trials will support approval, validation and/or reimbursement for our products,  as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. Company
OPKO Health, Inc.
David Malina, 305-575-4100

Investor Relations
or
Media
Rooney Partners
Terry Rooney, 212-223-0689
[email protected]
or
Marion Janic, 212-223-4017
[email protected]
or
Investors
LHA
Anne Marie Fields, 212-838-3777
[email protected]
or
Bruce Voss, 310-691-7100
[email protected] 


Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.71
OPK's PB Ratio is ranked higher than
64% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. OPK: 1.71 )
Ranked among companies with meaningful PB Ratio only.
OPK' s PB Ratio Range Over the Past 10 Years
Min: 1.74  Med: 8.48 Max: 800
Current: 1.71
1.74
800
PS Ratio 2.92
OPK's PS Ratio is ranked lower than
56% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. OPK: 2.92 )
Ranked among companies with meaningful PS Ratio only.
OPK' s PS Ratio Range Over the Past 10 Years
Min: 2.97  Med: 31.68 Max: 158.13
Current: 2.92
2.97
158.13
Price-to-Operating-Cash-Flow 536.67
OPK's Price-to-Operating-Cash-Flow is ranked lower than
95% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. OPK: 536.67 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OPK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 20.6  Med: 39.18 Max: 676.67
Current: 536.67
20.6
676.67
EV-to-EBIT -49.51
OPK's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. OPK: -49.51 )
Ranked among companies with meaningful EV-to-EBIT only.
OPK' s EV-to-EBIT Range Over the Past 10 Years
Min: -130.8  Med: -35.05 Max: 203.7
Current: -49.51
-130.8
203.7
EV-to-EBITDA 127.71
OPK's EV-to-EBITDA is ranked lower than
97% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. OPK: 127.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6  Med: -34.05 Max: 539.9
Current: 127.71
-146.6
539.9
Current Ratio 1.74
OPK's Current Ratio is ranked lower than
63% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. OPK: 1.74 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 5.3 Max: 415
Current: 1.74
0.88
415
Quick Ratio 1.56
OPK's Quick Ratio is ranked lower than
55% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. OPK: 1.56 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.75 Max: 415
Current: 1.56
0.48
415
Days Inventory 26.02
OPK's Days Inventory is ranked higher than
93% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. OPK: 26.02 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 25.94  Med: 191.87 Max: 500.07
Current: 26.02
25.94
500.07
Days Sales Outstanding 71.08
OPK's Days Sales Outstanding is ranked higher than
58% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. OPK: 71.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 153.78 Max: 727.85
Current: 71.08
38.86
727.85
Days Payable 43.98
OPK's Days Payable is ranked lower than
84% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. OPK: 43.98 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 31.85  Med: 108.04 Max: 1499.3
Current: 43.98
31.85
1499.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.60
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. OPK: -10.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3  Med: -14.4 Max: 0.4
Current: -10.6
-146.3
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 378.82
OPK's Price-to-Tangible-Book is ranked lower than
99.99% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. OPK: 378.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OPK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.35  Med: 10.28 Max: 850
Current: 378.82
0.35
850
Price-to-Intrinsic-Value-Projected-FCF 2.43
OPK's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
52% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. OPK: 2.43 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OPK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 3.02  Med: 10.97 Max: 177.5
Current: 2.43
3.02
177.5
Price-to-Median-PS-Value 0.09
OPK's Price-to-Median-PS-Value is ranked higher than
98% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. OPK: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.29 Max: 30
Current: 0.09
0.11
30
Earnings Yield (Greenblatt) % -2.02
OPK's Earnings Yield (Greenblatt) % is ranked lower than
73% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. OPK: -2.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 0.5 Max: 0.5
Current: -2.02

More Statistics

Revenue (TTM) (Mil) $1,227
EPS (TTM) $ -0.10
Beta2.19
Short Percentage of Float22.26%
52-Week Range $6.37 - 12.15
Shares Outstanding (Mil)559.39

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,244 1,389 1,550
EPS ($) -0.28 -0.17 0.03
EPS without NRI ($) -0.28 -0.17 0.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)
» More Articles for OPK

Headlines

Articles On GuruFocus.com
MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering May 22 2017 
OPKO Announces Multiple Presentations at the 112th American Urological Association Annual Meeting May 15 2017 
Weekly CEO Buys Highlights May 15 2017 
CORRECTION -- OPKO Health Inc. May 09 2017 
OPKO Health Reports 2016 Financial and Operating Results May 09 2017 
OPKO Health to Announce 2017 First Quarter Financial Results on May 9, 2017 May 08 2017 
Weekly CEO Buys Highlight May 01 2017 
Weekly CEO Buys Highlights Apr 24 2017 
Weekly CEO Buys Highlights Apr 10 2017 
Insiders Roundup: Apollo Global Management, Apple Apr 07 2017 

More From Other Websites
Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656... May 22 2017
MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering May 22 2017
OPKO Health’s 4Kscore® Test Highlighted in Podium Presentation at 112th American Urological... May 18 2017
Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update May 16 2017
Edited Transcript of OPK earnings conference call or presentation 9-May-17 8:30pm GMT May 15 2017
OPKO Announces Multiple Presentations at the 112th American Urological Association Annual Meeting  May 15 2017
OPKO Health reports 1Q loss May 09 2017
CORRECTION -- OPKO Health Inc. May 09 2017
OPKO Health Reports 2016 Financial and Operating Results May 09 2017
Investor Network: OPKO Health, Inc. to Host Earnings Call May 09 2017
Xenetic Biosciences to Host 2017 First Quarter Update Conference Call May 09 2017
ETFs with exposure to OPKO Health, Inc. : May 8, 2017 May 08 2017
OPKO Health to Announce 2017 First Quarter Financial Results on May 9, 2017 May 08 2017
Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein... May 01 2017
ETFs with exposure to OPKO Health, Inc. : April 27, 2017 Apr 27 2017
Cocrystal Pharma Receives Investment Through Private Placement Apr 24 2017
Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th... Apr 20 2017
3 Beaten-Up Healthcare Stocks: Are They Bargains? Apr 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}